Mark Liddament is a seasoned professional in molecular biology and biopharmaceutical research, currently serving as Senior Director and Head of Molecular Biology at CSL since June 2019, where leadership includes overseeing a global department focused on Cell Line Development, Gene Technologies, and Antibody Discovery. Prior roles encompass Director of Antibody Discovery and Protein Engineering at CSL, Associate Director at Teva Pharmaceuticals, and Principal Scientist at OBodies Ltd., highlighting a consistent track record of guiding teams in therapeutic antibody development. Earlier experiences include key positions at GlaxoSmithKline, MedImmune, and a postdoctoral fellowship at the University of Minnesota, complemented by a PhD in Biochemistry from the University of Cambridge and a BSc from Queen Mary, University of London.
This person is not in any teams
This person is not in any offices